Corilagin
Catalog No: CFN90176
Corilagin has antitumour, anti-inflammatory, antioxidant, antifibrotics, antiviral, antibacterial, hepatoprotective, antiatherogenic, and antihypertensive activities. Corilagin reduces the cytotoxicity induced by EV71 or CA16 on Vero cells with and IC50 value of 5.6 and 32.33 μg/mL, respectively; it shows the potential to protect against HSV-1-induced encephalitis, and the beneficial effects may be mediated by inhibiting TLR2 signaling pathways. Corilagin attenuates bleomycin-induced epithelial injury and fibrosis via inactivation of oxidative stress, proinflammatory cytokine release and NF-κB and TGF-β1 signaling; it suppresses the activity of beta-lactamase to some extent.
Cornuside
Catalog No: CFN98159
Cornuside has immunomodulatory, and anti-inflammatory activities, it has protective potential against cerebral ischemic injury, may be due to the suppression of intracellular Ca(2+) elevation and caspase-3 activity, and improvements in mitochondrial energy metabolism and antioxidant properties. Cornuside can treat myocardial I/R and protect the liver from CCl₄-induced acute hepatotoxicity, by reducing oxidative stress and suppressing inflammatory responses.
Coronarin A
Catalog No: CFN99301
Coronarin, A, B, C, and D are cytotoxic prinicples from the rhizomes of Hedychium coronarium, Zingiberaceae. Coronarin A exhibits good growth inhibition activities on HUVEC proliferation, it effectively suppresses the growth factor induced tube formation of HUVEC at the concentration of 10 microg/mL. Coronarin A has anti-inflammatory activity, it exhibits potent inhibition (IC50 <6.1708g/mL) against fMLP-induced superoxide production and elastase release.
Coronarin D
Catalog No: CFN99302
Coronarin D shows promising antifungal activity against C. albicans in vitro, the minimum inhibitory concentration (MIC) and the minimum fungicidal concentration (MFC) were 2 and 4 mg/mL, respectively; it is active against tested Gram-positive bacteria, inactive for tested Gram-negative bacteria, and weakly active against tested fungi; using coronarin D-antibiotic drug combination can combat the infectious diseases.Coronarin D inhibits NF-kappaB activation pathway, which leads to inhibition of inflammation, invasion, and osteoclastogenesis, as well as potentiation of apoptosis.
Corosolic acid
Catalog No: CFN98685
Corosolic acid has antitumor, anti-inflammatory and hypoglycemic activities, it can ameliorate hypertension, abnormal lipid metabolism, and oxidative stress as well as the inflammatory state in SHR-cp rats; it can improve glucose metabolism by reducing insulin resistance, it inhibits the enzymatic activities of several diabetes-related non-receptor protein tyrosine phosphatases (PTPs) in vitro, such as PTP1B, T-cell-PTP, src homology phosphatase-1 and src homology phosphatase-2. Corosolic acid can suppress the M2 polarization of macrophages and tumor cell proliferation by inhibiting both STAT3 and NF-κB activation, it also can enhance the antitumor effects of adriamycin and cisplatin in in vitro.